Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

LCTX

AMEX

Lineage Cell Therapeutics (LCTX)

1 USD −2.91% vs prior close Oct 30, 2026
Lineage Cell Therapeutics, Inc. price graph
26 sessions
1.05 0.90 25 Sep 30 Oct

The line runs 1 USD on 25 September through 1 USD on 30 October, on a scale from 0.90 to 1.05. Days the market did not trade hold the previous close, flat.

Market cap
253.0M USD
Revenue, year to Dec 2025
14.6M USD
EPS, diluted, year to Dec 2025
−0.28 USD
52-week range
0.9027 USD – 2 USD
Avg volume
91.0K

as of Oct 30, 2026

Have Lineage Cell Therapeutics (LCTX) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Lineage Cell Therapeutics insiders reported 5 open-market purchases and no sales (SEC Form 4).

Form 4, 90 days to 22 Nov 2026, newest reported trade 17 Nov 2026

5buys
0sells
$871Knet bought
0other filings
Have Lineage Cell Therapeutics (LCTX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
17 Nov 2026BROADWOOD PARTNERS, L.P.DirectorBuy1,000,000771K USD
17 Nov 2026Mulroy Michael H.DirectorBuy30,00026K USD
16 Nov 2026Howe Jill AnnChief Financial OfficerBuy20,00017K USD
16 Nov 2026ANDREWS DEBORAH JDirectorBuy25,00020K USD
16 Nov 2026Culley Brian MPresident and CEOBuy40,50037K USD
Bought5 open-market purchases1,115,500$871K

Which funds hold Lineage Cell Therapeutics (LCTX)?

7 of the 45 institutional funds we track reported a Lineage Cell Therapeutics position for the quarter ended 30 Sep 2026 — a combined 3.8M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Lineage Cell Therapeutics (LCTX)?
FundPositionSharesValueShares q/q
Millennium ManagementHeld (±25%)2,628,1502.5M USD−12.9%
Renaissance TechnologiesTrimmed674,529645K USD−49.8%
Citadel AdvisorsHeld (±25%)341,881327K USD−19.8%
Marshall WaceTrimmed203,391195K USD−84.1%
Two Sigma InvestmentsAdded127,573122K USD+132.2%
Point72 Asset ManagementNew position29,12828K USD
AQR Capital ManagementNew position12,09712K USD

What has been filed or recorded for Lineage Cell Therapeutics (LCTX)?

The filings we hold for Lineage Cell Therapeutics, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Lineage Cell Therapeutics (LCTX)?
And
30 Oct 2026Fails to deliverShares failed to deliver4,298 shares4K USD notional · 0.002% of shares out
23 Oct 2026Fails to deliverShares failed to deliver24,893 shares25K USD notional · 0.010% of shares out
14 Oct 2026Fails to deliverShares failed to deliver26,826 shares24K USD notional · 0.011% of shares out
09 Oct 2026Fails to deliverShares failed to deliver9,441 shares10K USD notional · 0.004% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.03 USDRevenue $1M
30 Sep 2026FinancialsTotal assets100.1M USDat period end
30 Sep 2026FinancialsTotal equity67.1M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.03 USDRevenue $1M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.03 USDRevenue $2M
31 Dec 2025Annual reportFY 2025 reportedEPS −0.28 USDRevenue $15M
31 Dec 2025FinancialsRevenue14.6M USDfiscal year
31 Dec 2025FinancialsNet income−63.5M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−0.28 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.13 USDRevenue $4M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.13 USDRevenue $3M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.02 USDRevenue $2M
31 Dec 2024Annual reportFY 2024 reportedEPS −0.09 USDRevenue $9M

What do people ask about Lineage Cell Therapeutics (LCTX)?

From live data
What did Lineage Cell Therapeutics shares close at?1.00

Lineage Cell Therapeutics closed at 1.00 USD on 30 Oct 2026, down 2.91% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Lineage Cell Therapeutics’ market cap?253.0M

Lineage Cell Therapeutics is worth 253.0M USD by market value as of 30 Oct 2026, which is the share price times the shares on issue from its SEC filings.

What is Lineage Cell Therapeutics’ revenue?14.6M

Lineage Cell Therapeutics reported revenue of 14.6M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Lineage Cell Therapeutics insiders bought or sold shares recently?5 purchases

In the 90 days to 22 Nov 2026, Lineage Cell Therapeutics insiders reported 5 open-market purchases and no sales (SEC Form 4). See Insiders

Which funds own Lineage Cell Therapeutics?7 of 45

7 of the 45 funds we track reported a Lineage Cell Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Renaissance Technologies and Citadel Advisors. See Funds

When did Lineage Cell Therapeutics last report earnings?−0.03

Lineage Cell Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.03 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. Company websiteAbout text: the company's own website, summarised in our own words